ARM Holdings reported strong third-quarter earnings and gave investors a solid, but not spectacular, fourth-quarter outlook that was relatively in line with our expectations. We will maintain our moat rating for ARM but may raise our fair value estimate by about 10%. Nonetheless, we still believe the company’s stock price reflects overly optimistic assumptions about…
BlackBerry (BBRY, BB.TO) reported a Q4 adjusted loss of $0.08 per share, better than expectations of a loss of $0.54 per share, if comparable. Revenue was $976 million, down 64% from $2.7 billion in the year ago quarter, and below the analyst consensus of $1.2 billion on Capital IQ. During Q4, the company recognized hardware…
Shares of HomeAway (NASDAQ:AWAY) are dipping in after-hours trade as the online vacation rental company said it intends to offer $350 million aggregate principal amount of convertible senior notes due 2019 in a private placement to qualified institutional buyers, as well as expects to grant the initial purchasers of the notes a 30-day option to…
SciQuest (NASDAQ:SQI) said it is starting an underwritten public offering of 3,000,000 shares of common stock pursuant to an effective shelf registration statement. The last reported sale price of the company’s common stock on March 21, 2014 was $30.41 per share. The company also intends to grant the underwriters an option to purchase up to…
Dover (DOV) was started with a Neutral rating at Goldman Sachs, and shares nosed down less than 1%. Goldman placed an $88 price target on the shares of the diversified manufacturer. In afternoon trade, DOV was off 0.33% to $81.20. Insulet (PODD) was started with a buy rating at Sterne Agee. Shares fell less than 1%. vSterne…
Celgene Corp (NASDAQ:CELG) was unchanged in Friday’s after-market and the biotech company confirmed the U.S. Food and Drug Administration has approved the company’s psoriatic arthritis treatment, the first of its kind in this country. The drug will be marketed commercially as Otezla. According to the company, the drug works differently than other approved therapies through…
